Drug Disposition & Biological Products

Pharmacokinetic studies are more important for therapeutic biologics. Identifying the key factors that govern absorption, distribution, metabolism, and excretion of biologics as therapeutic agents improved the opportunities for the scientists working in drug disposition research field. The European Union (EU) first approved a biologic in 2006, now there are more than 700 biosimilars approved or in the pipeline globally. Analysts expect the worldwide biosimilars market to reach $25 billion to $35 billion by 2020. Generics have larger share of total global medicine spend, increasing from 27 percent ($261 billion) in 2012 to 36 percent ($421 billion) by 2017.

    Related Conference of Drug Disposition & Biological Products

    June 08-09, 2018

    7th International conference on Pharmaceutical Auditing

    Baltimore, Maryland, USA
    June 27-28, 2018

    4th International Conference on Drug Discovery, Designing and Development

    Vancouver, British Columbia, Canada
    August 20-21, 2018

    9th Asian Biologics and Biosimilars Congress

    Tokyo, Japan
    October 18-19, 2018

    18th World Pharma Congress

    Warsaw, Poland
    August 15-17, 2018

    8th World Congress Spectroscopy and Analytical Techniques

    Stockholm, Sweden
    September 18-19, 2018

    6th European Biopharma Congress

    Amsterdam, Netherlands

    Drug Disposition & Biological Products Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in